NRx Pharmaceuticals, Inc. (NRXPW) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 2 Buy.
Analysts estimate Earnings Per Share (EPS) of $-1.91 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.39 vs est $-1.91 (missed -25.3%). 2025: actual $-1.34 vs est $-1.04 (missed -29.2%). Analyst accuracy: 79%.
NRXPW Analyst Ratings
Buy
Based on 2 analysts giving stock ratings to NRx Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — NRXPW
79%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$2.39
vs Est –$1.91
▼ 20.2% off
2025
Actual –$1.34
vs Est –$1.04
▼ 22.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — NRXPW
0%
Analyst Accuracy
Inaccurate
1 year compared
Actual vs Estimate
2025
Actual $0.001B
vs Est $0.012B
▼ 864.1% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast revenue contraction ahead.
